BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30371509)

  • 1. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
    Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
    Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
    Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
    Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
    Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical variants of nodular lymphocyte-predominant Hodgkin lymphoma show low microvessel density and vessels of distention type.
    Scheidt V; Hansmann ML; Schuhmacher B; Döring C; Hartmann S
    Hum Pathol; 2017 Feb; 60():129-136. PubMed ID: 27816718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?
    Hartmann S; Döring C; Jakobus C; Rengstl B; Newrzela S; Tousseyn T; Sagaert X; Ponzoni M; Facchetti F; de Wolf-Peeters C; Steidl C; Gascoyne R; Küppers R; Hansmann ML
    PLoS One; 2013; 8(11):e78812. PubMed ID: 24244368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.
    Hartmann S; Tousseyn T; Döring C; Flüchter P; Hackstein H; Herreman A; Ponzoni M; de Wolf-Peeters C; Facchetti F; Gascoyne RD; Küppers R; Steidl C; Hansmann ML
    Int J Cancer; 2013 Dec; 133(11):2609-18. PubMed ID: 23686423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
    Tian X; Xu J; Fletcher C; Hornick JL; Dorfman DM
    Mod Pathol; 2018 Apr; 31(4):553-561. PubMed ID: 29327713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.
    Tousseyn TA; King RL; Fend F; Feldman AL; Brousset P; Jaffe ES
    Virchows Arch; 2023 Jan; 482(1):207-226. PubMed ID: 36274093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
    Wu D; Thomas A; Fromm JR
    Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
    Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
    J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
    Bakshi NA; Finn WG; Schnitzer B; Valdez R; Ross CW
    Arch Pathol Lab Med; 2007 May; 131(5):742-7. PubMed ID: 17488159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
    Browne P; Petrosyan K; Hernandez A; Chan JA
    Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
    Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
    Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.
    Bohn O; Maeda T; Filatov A; Lunardi A; Pandolfi PP; Teruya-Feldstein J
    Int J Surg Pathol; 2014 Feb; 22(1):6-11. PubMed ID: 24326827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.